Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA4 | P22748 | 6/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17282361 | 0.92 | CRBN (0.41) | CA2CA9CA12CA1CA4 | |
| SCHEMBL18886281 | 0.92 | CRBN (0.41) | CA2CA9CA12CA1CA4 | |
| SCHEMBL19138454 | 0.88 | CA2 (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL20883229 | 0.87 | CRBN (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL20552921 | 0.87 | CRBN (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL23157563 | 0.87 | CRBN (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL23157517 | 0.87 | CRBN (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL30737963 | 0.86 | GAA (0.41) | CRBNGAAKDM4EKDM5CPHF8 | |
| SCHEMBL29496150 | 0.86 | GAA (0.41) | CRBNGAAKDM4EKDM5CPHF8 | |
| SCHEMBL26617637 | 0.85 | CRBN (0.37) | CA2CA9CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-05-26 | — | — | US | disclosed |
| WO-2020210692-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210694-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, NCL, PBRM1 | CA2 2294/4885CA9 3351/4885CA12 2584/4885 |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | CA2 2260/4885CA9 3033/4885CA12 2163/4885 |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | CA2 2274/4885CA9 3038/4885CA12 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.